
Using good ole hindsight but that is the only thing you can base your decision on, for better or worse, not a share to re-invest your dividends in.


Not a share you might have bought for your Snowball as until recently as the share price has fallen the dividend increased enough to take the risk.
Current yield 8%

Assura plc, the UK’s leading diversified healthcare REIT, is pleased to announce it has exchanged on the disposal of seven assets for a gross consideration of £64 million.
The latest disposals mean that since the start of the financial year, the Company has sold 30 assets for gross proceeds of £200 million at a weighted average net initial yield of 4.8%.
The net proceeds have been deployed in reducing the acquisition debt used to finance the £500 million private hospital portfolio acquired in August 2024 at 5.9% yield on cost.
The disposal announced today marks further progress in Assura’s overall debt reduction plans and the Company’s proforma net LTV will reduce to 47%.
The sale also reinforces that the quality of the Company’s portfolio and the resilience of its underlying cash flows remain highly attractive to the investment market.
The disposal is immediately earnings enhancing as the cash receipts will be used to repay the revolving credit facility.
The seven assets disposed of today have been sold into Assura’s £250 million joint venture. Assura retains a 20% equity interest in the joint venture resulting in net proceeds of £51 million. Following this transaction, the joint venture has gross assets of £172 million. Assura continues to act as property and asset manager to the joint venture, receiving management fees linked to the valuation of the portfolio.
Jonathan Murphy, CEO, said:
“Reaching this £200 million milestone in our disposal programme means we are on track to achieve our target of net debt to EBITDA below 9 times and LTV below 45% well ahead of the previously outlined timetable. This accelerated delivery and our ability to achieve sales is testament to our operational excellence and the quality and attractiveness of our property portfolio.
“The disposal programme was announced at the time of our transformational acquisition of high-quality private hospital assets in August 2024. The acquisition has positioned Assura as a leader in a structurally supported market, and has cemented our position as the UK’s leading diversified healthcare REIT offering an attractive investment opportunity into favourable long-term trends.”
Notice of Dividend
Assura plc (“Assura” or “the Company”), UK’s leading diversified healthcare REIT, today announces that the next quarterly interim dividend of 0.84 pence per share will be paid on 9 April 2025 to shareholders on the register on 7 March 2025 (the “Record Date”). The Ex-dividend Date will be 6 March 2025.
18 February 2025
Statement re Possible Offer from Kohlberg Kravis Roberts & Co. Partners L.L.P. (“KKR”)
The Board of Assura plc (“Assura” or the “Company”) notes the announcement from KKR yesterday relating to the indicative, non-binding proposal that it submitted to the Assura Board on 13 February 2025 regarding a possible cash offer for the entire issued share capital of the Company at 48 pence per share (the “Proposal”).
The Board confirms that it considered the Proposal carefully with its advisers and concluded that it materially undervalued the Company and its prospects and therefore rejected it unanimously. No further proposal from KKR has been received.
The Board of Assura also notes the announcement yesterday from USS Investment Management Limited (as agent for and on behalf of Universities Superannuation Scheme Limited (acting in its capacity as sole corporate trustee of the Universities Superannuation Scheme)) (“USSIM”) of its intention not to make an offer for Assura, as part of a consortium with KKR or otherwise, other than in the circumstances set out in USSIM’s announcement.
The Board remains confident in the long-term prospects of the Company and believes that Assura is strongly positioned to create value for shareholders.
Shareholders are advised to take no action.
A further announcement will be made as appropriate.
Under Rule 2.6(a) of the Code, KKR must by no later than 5.00 p.m. on 14 March 2025, either announce a firm intention to make an offer for Assura in accordance with Rule 2.7 of the Code or announce that it does not intend to make an offer, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies. This deadline will only be extended with the consent of the Panel in accordance with Rule 2.6(c) of the Code.
This announcement has been made without the consent of KKR.





